{‘She has no expertise’: the American medical establishment braces for Høeg's tenure at the Food and Drug Administration.

While the United States continues making unprecedented revisions to its immunization recommendations, a particular individual appears in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by expressing skepticism about COVID-19 shots throughout the pandemic and has zeroed in on possible deaths following COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Program

Public health authorities were set to announce radical revisions to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US out of alignment with much of the global community with insufficient data for public health gain. The announcement has been pushed back until the coming year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

A New Direction at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing specific childhood immunization guidelines in the US in order to be more similar to the Danish model, a country with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – usually the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Expertise

The appointee has little discernible experience in drug development, regulation or management, which has been typical for past heads of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in leading a sizeable institution. She is not an expert in drug approvals.”

Former commissioners of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Objectively, she lacks the kind of background that prior appointees who led the center have had.”

CDER has an enormous workload at the agency, the former commissioner emphasized.

“Many people just pays attention on the new drug program, but the generic program clears a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and every single one have to be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a major management component to the role, which manages more than 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” Woodcock said.

Response and Disputed Policies

In response to concerns about Høeg’s qualifications and whether this appointment represents increased cooperation among agency officials on vaccines, a press secretary stated that the “inquiries are based on inaccurate assumptions”.

“Her resume is consistent with the responsibilities of her position,” the representative said, noting the months Høeg spent advising the agency head on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s new expedited review system, a controversial rapid medication authorization process that reportedly worried her predecessors. “How are these medications being selected for this voucher program? Who takes the choices?” Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards less stringent regulations of all drugs, except for vaccines.”

Documented Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, past, some experts have noted. She published a study using unconfirmed public submissions to estimate the incidence of heart inflammation after Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are more dangerous than they are.

Among her “wish list” for the new government included altering guidelines for novel immunizations and ending “unnecessary” immunizations, she stated after the election on a online show. At the agency, Høeg has allegedly floated the idea of barring teenage boys from getting COVID-19 vaccinations.

“She’s an all-around ideologue who starts off with her preconceived notions and reverse-engineers to accommodate the data in a highly misleading, fraudulent way,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|